
AVXL Stock Forecast & Price Target
AVXL Analyst Ratings
Bulls say
Anavex Life Sciences is poised for success due to its focused pipeline of neurodegenerative and neurodevelopmental disease treatments, which have shown promising results and high potential for addressing unmet needs. The company has continued to engage with regulators in both the US and EU, providing additional data and clarifying its regulatory pathway, while maintaining a strong dialogue with European regulators. The strategic decision to withdraw its application in Europe demonstrates management's commitment to strengthening its data package and approaching regulators from a more informed standpoint. With a diverse and innovative pipeline and a strategic approach to regulatory engagement, Anavex has the potential for significant long-term growth.
Bears say
Anavex Life Sciences is facing a setback with the withdrawal of its EU marketing application for blarcamesine in early Alzheimer's disease due to negative feedback from the EMA. With this strategic reset, the company plans to incorporate additional data and resubmit the application in the future. However, its ongoing regulatory engagement in the US and upcoming data disclosures in Alzheimer's disease and other indications show potential for future growth.
This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
AVXL Analyst Forecast & Price Prediction
Start investing in AVXL
Order type
Buy in
Order amount
Est. shares
0 shares